You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
仟源醫藥(300254.SZ):以1.09億元轉讓相關資產
格隆匯 07-03 00:07

格隆匯7月3日丨仟源醫藥(300254.SZ)公佈,為了盤活資產,優化資產結構,避免較大規模新廠區固定資產投資,同時基於未來公司集中化生產的戰略佈局,從而有效降低公司藥品生產多基地運營的成本,進一步提升公司的盈利能力。2023年3月6日公司召開了第五屆董事會第二次會議審議通過了與山西雙雁藥業有限公司(“雙雁藥業”)簽署《資產出售框架協議》。目前出售資產的相關準備工作已完成,雙方本着公平合理的原則簽訂正式的《資產出售協議》,公司以人民幣10945.51萬元轉讓位於大同市經濟技術開發區恒安街1378號及位於大同市經濟技術開發區第二醫藥園區的土地使用權、房產及其他地上建築物/附着物、在建工程,部分生產設備,一批雙雁藥業認可及需要的藥品上市許可。

自公司原主要產品注射用美洛西林鈉舒巴坦鈉等退出國家醫保後,大同廠區粉針劑生產線基本處於停產狀態,同時,位於大同經濟技術開發區第二醫藥園區的土地及在建工程也一直處於閒置狀態,此次資產出售有利於公司盤活資產,優化資產結構。

此次大同廠區資產出售是公司未來集中化生產的戰略佈局,有利於公司資源整合,有效降低公司藥品生產多基地運營的成本,進一步提升公司的盈利能力。

大同現有生產廠區未來涉及整體搬遷,此次資產出售後公司將不再需要投入大量資金進行新廠區建設,避免了較大規模的固定資產投資,從而降低了公司的運營成本和財務風險。

公司轉讓的藥品上市許可品種2022年度營業收入佔公司總營業收入不超過2%,不會對公司經營業績產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account